Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement

Cancer

Volumn 117, Issue 6, 2011, Pages 1296-1301

  Erinjeri, Joseph P ^a   Fong, Abigail J ^a   Kemeny, Nancy E ^a   Brown, Karen T ^a   Getrajdman, George I ^a   Solomon, Stephen B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

bevacizumab; chest wall port; dehiscence; wound healing

Indexed keywords

BEVACIZUMAB;

ADULT; APPENDIX CANCER; ARTICLE; BREAST CANCER; CANNULATION; CHEST WALL PORT PLACEMENT; COLORECTAL CANCER; CONTROLLED STUDY; DEVICE REMOVAL; EROSION; FEMALE; FEVER; HUMAN; INFECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RISK FACTOR; WOUND DEHISCENCE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CATHETERIZATION; CATHETERS, INDWELLING; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURGICAL WOUND DEHISCENCE; THORACIC WALL; TIME FACTORS; WOUND HEALING;

EID: 79952425597     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25573     Document Type: Article

References (29)

1. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362: 841-844. (Pubitemid 23132159)
2. Breen EC., VEGF in biologic control. J Cell Biochem. 2007; 102: 1358-1367.
3. Coultas L, Chawengsaksophak K, Rossant J., Endothelial cells and VEGF in vascular development. Nature. 2005; 438: 937-945. (Pubitemid 43093959)
4. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR., Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 1995; 107: 233-235.
5. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA., Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 1998; 152: 1445-1452. (Pubitemid 28275003)
6. Ferrara N., VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002; 2: 795-803. (Pubitemid 37328914)
7. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57: 4593-4599. (Pubitemid 27441066)
8. Jenab, -Wolcott J, Giantonio BJ., Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009; 9: 507-517.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550. (Pubitemid 44917502)
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
12. Saif MW, Mehra R., Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006; 5: 553-566. (Pubitemid 44468452)
13. Verheul HM, Pinedo HM., Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007; 7: 475-485. (Pubitemid 46809172)
14. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19: 843-850. (Pubitemid 32119100)
15. Schwarz RE, Groeger JS, Coit DG., Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer. 1997; 79: 1635-1640. (Pubitemid 27154800)
16. Lorch H, Zwaan M, Kagel C, Weiss HD., Central venous access ports placed by interventional radiologists: experience with 125 consecutive patients. Cardiovasc Intervent Radiol. 2001; 24: 180-184. (Pubitemid 32587872)
17. Funaki B, Szymski GX, Hackworth CA, et al. Radiologic placement of subcutaneous infusion chest ports for long-term central venous access. AJR Am J Roentgenol. 1997; 169: 1431-1434. (Pubitemid 27452516)
18. Morris JA, Gardner MJ., Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988; 296: 1313-1316.
19. Avastin (bevacizumab) prescribing information. Available at: Accessed October 4, 2010.
20. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91: 173-180. (Pubitemid 41254420)
21. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23: 3697-3705.
22. D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007; 14: 759-765. (Pubitemid 46175324)
23. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009; 20: 985-992.
24. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008; 26: 1830-1835.
25. Ellis LM, Curley SA, Grothey A., Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005; 23: 4853-4855. (Pubitemid 46223989)
26. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008; 206: 96-106. (Pubitemid 350267242)
27. Thornton AD, Ravn P, Winslet M, Chester K., Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006; 93: 1456-1463. (Pubitemid 44893645)
28. Broughton G Jr, Janis JE, Attinger CE., The basic science of wound healing. Plast Reconstr Surg. 2006; 117 (suppl): 12S-34S. (Pubitemid 44317769)
29. Zawacki WJ, Walker TG, Devasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol. 2009; 20: 624-627.